Curran Daniel J. 4

What Happened

Daniel J. Curran, a director of Xilio Therapeutics (XLO), was granted a derivative award covering 5,000 shares on June 11, 2026. The filing reports an acquisition at a reported price of $0.00 (total reported value $0), indicating an option/award rather than an open-market purchase or sale. This is a grant of equity compensation, not a cash purchase or disposition.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely).
• Award: 5,000 shares (derivative award/option) at reported price $0.00.
• Vesting: 100% of the shares vest on the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing timeliness: Filed the next day; not marked late.

Context

This was an equity award to a director as part of compensation governance; it does not represent an immediate purchase or sale of market stock. The award vests contingent on continued service and a date condition, so the shares will only become owned/transferable if/when vesting conditions are met. Such grants are common for directors and do not by themselves indicate a personal purchase or sale intent.